Zydus Cadila to market drug to treat inflammatory bowel ailments
DSIJ Intelligence / 14 Aug 2017
Zydus Cadila has received approval from the USFDA to market Mesalamine Suppositories (1,000 mg), which is used to treat inflammatory bowel diseases such as ulcerative colitics.
Zydus Cadila has received approval from the USFDA to market Mesalamine Suppositories (1,000 mg), which is used to treat inflammatory bowel diseases such as ulcerative colitics. The drug will be produced at the company’s Ahmedabad plant.
With this most recent approval, Zydus Cadila has more than 140 approvals. In addition, since the commencement of the filing process in FY2003-04, it filed over 300 ANDAs.
The company’s stock was trading higher by 1.88% at Rs 492 per share on the BSE at 0918 hours. It opened at Rs 475 per share and has attracted a total traded volume of 46,718 shares and value of Rs 228.43 lakhs on the NSE at 0920 hours.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.